EI
SWTX

Ellevest Inc’s SpringWorks Therapeutics SWTX Stock Holding History

Ellevest Inc’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8
Closed -$206 – 1465
2023
Q1 		$206 Buy
+8
New +$234 ﹤0.01% 1767
2022
Q4 		– Sell
-13
Closed – – 1954
2022
Q3 		$0 Sell
13
-4
-24% -$115 ﹤0.01% 1855
2022
Q2 		$0 Buy
+17
New +$622 ﹤0.01% 1678

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ellevest Inc's SWTX Position: Q2 2023 in Review

Ellevest Inc sold out of SpringWorks Therapeutics (SWTX) in Q2 2023, closing a stake of 8 shares — an estimated $206 sold.

Ellevest Inc first reported a position in SWTX in Q2 2022 and held it in 3 quarters. The position peaked at $206 in Q1 2023. 141 funds tracked by Wall St. Rank hold SWTX as of Q2 2023.

  • Ellevest Inc reported no remaining SpringWorks Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ellevest Inc sold 8 SpringWorks Therapeutics shares in Q2 2023, an estimated $206.
  • Ellevest Inc first reported a position in SpringWorks Therapeutics in Q2 2022 and held it in 3 quarters.
  • Ellevest Inc's SpringWorks Therapeutics position peaked at $206 in Q1 2023.
  • 141 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.